KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Free Cash Flow (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Free Cash Flow for 8 consecutive years, with -$26.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 70.74% to -$26.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$396.6 million through Dec 2025, up 12.57% year-over-year, with the annual reading at -$396.6 million for FY2025, 12.57% up from the prior year.
  • Free Cash Flow hit -$26.2 million in Q4 2025 for Vir Biotechnology, up from -$167.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $939.5 million in Q2 2022 to a low of -$398.7 million in Q2 2023.
  • Historically, Free Cash Flow has averaged -$6.2 million across 5 years, with a median of -$89.8 million in 2021.
  • Biggest five-year swings in Free Cash Flow: surged 1178.84% in 2021 and later crashed 585.38% in 2023.
  • Year by year, Free Cash Flow stood at -$5.4 million in 2021, then soared by 519.81% to $22.6 million in 2022, then plummeted by 585.38% to -$109.5 million in 2023, then grew by 18.12% to -$89.6 million in 2024, then surged by 70.74% to -$26.2 million in 2025.
  • Business Quant data shows Free Cash Flow for VIR at -$26.2 million in Q4 2025, -$167.9 million in Q3 2025, and -$122.8 million in Q2 2025.